Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR-hTNF + Doxorubicin in Advanced SCLC
NCT00483509Phase 2Completed
- Sponsor
- AGC Biologics
- Start
- Feb 2007
- Primary completion
- Sep 2010
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NGR-TNF in Small Cell Lung Cancer (SCLC), sponsored by AGC Biologics. Primary endpoint: Progression Free Survival up to 150 weeks. Started Feb 2007; status: completed.
02
Drugs
NGR-TNF
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT00483509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483509.